ICU Medical (NASDAQ:ICUI) Rating Lowered to Hold at Wall Street Zen

ICU Medical (NASDAQ:ICUI) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. KeyCorp increased their target price on shares of ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Piper Sandler lifted their price target on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, ICU Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.67.

ICU Medical Stock Performance

ICU Medical stock opened at $152.99 on Friday. The firm has a 50 day simple moving average of $143.10 and a 200-day simple moving average of $131.47. The stock has a market cap of $3.78 billion, a price-to-earnings ratio of -493.50 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.45 and a quick ratio of 1.19. ICU Medical has a 1-year low of $107.00 and a 1-year high of $175.51.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. The firm had revenue of $533.30 million for the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The firm’s quarterly revenue was down 8.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.59 earnings per share. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, analysts expect that ICU Medical will post 4.11 EPS for the current year.

Insider Buying and Selling at ICU Medical

In related news, Director Elisha W. Finney sold 1,285 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the transaction, the director directly owned 3,995 shares of the company’s stock, valued at $560,977.90. The trade was a 24.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Virginia Ruth Sanzone sold 930 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total transaction of $132,376.20. Following the sale, the vice president owned 5,456 shares in the company, valued at $776,607.04. The trade was a 14.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently modified their holdings of ICUI. Arizona State Retirement System increased its holdings in ICU Medical by 1.3% in the third quarter. Arizona State Retirement System now owns 6,903 shares of the medical instruments supplier’s stock valued at $828,000 after buying an additional 91 shares during the last quarter. Moody National Bank Trust Division boosted its position in shares of ICU Medical by 0.9% during the 2nd quarter. Moody National Bank Trust Division now owns 10,751 shares of the medical instruments supplier’s stock worth $1,421,000 after acquiring an additional 93 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after acquiring an additional 101 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of ICU Medical by 4.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,459 shares of the medical instruments supplier’s stock valued at $325,000 after acquiring an additional 107 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its position in shares of ICU Medical by 0.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 18,098 shares of the medical instruments supplier’s stock worth $2,392,000 after acquiring an additional 114 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.